APOL1 肾病疗法是否一直隐藏在人们的视线中？

IF 14.8 1区医学 Q1 UROLOGY & NEPHROLOGY

Kidney international Pub Date : 2024-11-20 DOI:10.1016/j.kint.2024.09.003

Opeyemi A. Olabisi

{"title":"APOL1 肾病疗法是否一直隐藏在人们的视线中？","authors":"Opeyemi A. Olabisi","doi":"10.1016/j.kint.2024.09.003","DOIUrl":null,"url":null,"abstract":"<div><div>Two coding variants of <em>APOL1</em> account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci <em>et al.</em> reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1–induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 6","pages":"Pages 1015-1017"},"PeriodicalIF":14.8000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Has APOL1 kidney disease treatment been hiding in plain sight?\",\"authors\":\"Opeyemi A. Olabisi\",\"doi\":\"10.1016/j.kint.2024.09.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Two coding variants of <em>APOL1</em> account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci <em>et al.</em> reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1–induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.</div></div>\",\"PeriodicalId\":17801,\"journal\":{\"name\":\"Kidney international\",\"volume\":\"106 6\",\"pages\":\"Pages 1015-1017\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2024-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0085253824006434\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0085253824006434","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

APOL1 的两个编码变体是西非近亲患局灶节段性肾小球硬化症风险过高的主要原因。脂蛋白 L1 肾病的治疗需求尚未得到满足。在本期杂志中，Sula Karreci 等人报告说，在载脂蛋白 L1 诱导的局灶节段性肾小球硬化小鼠模型中，利辛普利能以基因型特异性的方式减少蛋白尿和肾小球硬化。相比之下，水拉汀和达帕利洛嗪则没有影响。这项研究强调了血管紧张素转换酶抑制剂对载脂蛋白 L1 肾病的潜在治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Has APOL1 kidney disease treatment been hiding in plain sight?

Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1–induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kidney international 医学-泌尿学与肾脏学

CiteScore

23.30

自引率

3.10%

发文量

490

审稿时长

3-6 weeks

期刊介绍： Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.